Company: XOMAP
Filing Date: 2025-02-11
Form Type: 8-K/A
Source: 0001193125-25-024024
Chunk: 1

Company: XOMA Royalty Corp
Filing Date: 2025-02-11
Form: 8-K/A
Chunk 1
---
8.375% Series B Cumulative Perpetual Preferred Stock, par value $0.05 per share) |     | XOMAO     |     | The Nasdaq Global Market |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

EXPLANATORY NOTE On December 2, 2024, XOMA Royalty Corporation (the “ Company” or “ XOMA”) filed a Current Report on Form 8-Kwith the Securities and Exchange Commission (the “ Original Form 8-K”) reporting the Company’s completion of the acquisition of Pulmokine, Inc., a Delaware corporation (“ Pulmokine”), pursuant to an Agreement and Plan of Merger, dated as of November 26, 2024 in exchange for a $20 million cash payment at closing. The Company is filing this amendment to the Original Form 8-K(“ Amendment”) to amend and supplement the Original Form 8-Kto include historical financial statements of Pulmokine and pro forma financial information as required by Items 9.01(a) and 9.01(b), respectively, of Form 8-Kand that were excluded from the Original Form 8-Kin reliance on the instructions to such items. Except as noted in this paragraph, no other information contained in the Original Form 8-Kis amended or supplemented. This Amendment should be read together with the Original Form 8-K.

| Item 9.01 | Financial Statements and Exhibits. |

(a) Financial Statements of Businesses Acquired The financial statements of Pulmokine as of and for the year ended December 31, 2023 (audited) and as of and for the nine months ended September 30, 2024 (unaudited) are filed as Exhibit 99.2 and Exhibit 99.3 to this Amendment. (b) Pro Forma Financial Information The unaudited pro forma condensed combined balance sheet as of September 30, 2024, the unaudited pro forma